Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this post-marketing surveillance study is to collect and assess data
related to the safety and effectiveness of Harvoni® (ledipasvir/sofosbuvir (LDV/SOF))
treatment regimen, per the approved Korea prescribing information for Harvoni, in routine
clinical practice in Korea and to report the results to the Ministry of Food and Drug Safety
(MFDS). Participants will be treated as part of routine practice at Korean healthcare centers
by accredited physicians.
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir